Cytokinetics (CYTK) Jefferies Global Healthcare Conference 2026 summary

Key clinical data and feedback

• Top-line results for aficamten in non-obstructive HCM (ACACIA-HCM) met both dual primary endpoints, with robust and consistent effect sizes across endpoints and time points.

• Clinicians and academic leaders have expressed strong enthusiasm, describing the results as transformative and clinically meaningful.

• The magnitude of KCCQ improvement in the 500-patient study was double or more compared to typical heart failure studies, indicating a significant clinical benefit.

• Consistency and early onset of effect were observed, with improvements growing over time and persisting across subgroups.

• Secondary endpoints such as NYHA class and BNP are highlighted as important for real-world clinical relevance and will be closely watched in future data presentations.

Market opportunity and physician adoption

• Updated epidemiology suggests non-obstructive HCM (nHCM) now represents about 50% of the total HCM market, with diagnoses potentially growing faster than obstructive HCM.

• Physician feedback validates the 50/50 split and indicates accelerated growth in the nHCM segment.

• Some clinics have already shifted to 100% new CMI starts with MYQORZO after gaining experience, reflecting growing confidence and workflow adjustments.

• Market expansion is occurring as more physicians outside Centers of Excellence and new patient populations adopt the therapy.

• The launch trajectory and patient adds are outpacing initial expectations, suggesting a broader total addressable market.

Regulatory and safety considerations

• Discussions with regulators focus on providing comprehensive data for informed decision-making, with collaborative and transparent approaches anticipated.

• Monitoring of LVEF is critical, especially in nHCM where dosing is to maximal tolerated dose, leading to more LVEF excursions but aligning with real-world practice.

• FDA requires risk assessment at Cmax for cardiac myosin inhibitors, and REMS was imposed even with no dose interruptions due to LVEF drops in heart failure.

• Dose interruptions due to heart failure, rather than just LVEF drops, are considered more significant for regulatory evaluation.

• Ongoing open-label extension studies (FOREST) will provide further insights into safety and real-world management.